| Chemical Properties | Back Directory | [Boiling point ]
1655.6±65.0 °C(Predicted) | [density ]
1.429±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
1.83±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa)[1][2]. | [in vivo]
PSMA I&T (0.1-1 nM, intravenous injection, single dose) shows specific accumulation in mouse xenografts, kidneys, spleens, lungs, salivary glands, and adrenal glands[1]. | Animal Model: | Mice injected with LNCaP or LS174T-PSMA cells[1] | | Dosage: | 0.1-1 nM (0.2 MBq); single dose | | Administration: | Intravenous injection (i.v.) | | Result: | Showed dose-dependent uptake in PSMA-expressing tumors, kidney, spleen, adrenal glands, lung, and salivary glands. |
| [References]
[1] Chatalic KL, et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6(6):849-61. DOI:10.7150/thno.14744
[2] Amelie Heesch, et al. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer. Breast Cancer Res. 2024 Feb 20;26(1):30. DOI:10.1186/s13058-024-01787-9 |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
|